CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

Wegovy (semaglutide) is an FDA-approved medication for chronic weight management. Learn more about Wegovy, including how it works and potential risks.

Wegovy seems to be more effective for weight loss. Research shows semaglutide can lead to weight loss in a dose-dependent fashion — that is, the higher the dose, the more effective it is.

Novo Nordisk has launched Wegovy, a once-weekly weight-loss injection, in India. The drug aims to manage obesity and reduce ...

Since the GLP-1 drugs, including Mounjaro, Ozempic and Wegovy, were licensed, there have been hundreds of reported cases of ...

Weight-Loss Drugs Have Sent a Shocking Number of People to the Emergency Room, New Study Claims Researchers believe nearly 25,000 hospital visits occurred, mostly due to gastrointestinal complications ...

Both drugs led to substantial weight loss, but Mounjaro's 20% weight reduction, after 72 weeks of treatment, exceeded the 14% from Wegovy. More in Health A 51-year-old says she's in the best shape ...

Trial reveals if Zepbound or Wegovy is better for weight loss Why you should care: People taking Zepbound, Eli Lilly’s obesity drug, lost almost 50% more weight than individuals using Novo ...

Pharma giants are sweating on the results of a federal government request for guidance on adding weight loss drugs to the ...

The weight loss and diabetes drug, which is only available on prescription, should be on pharmacy shelves within days ending ...

After 72 weeks of treatment, people taking Zepbound lost about 50 pounds, compared with 33 pounds for those taking Wegovy. The weight loss drug Zepbound (tirzepatide) led to 50 percent more weight ...